BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.32 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 3.78M

Average 4.85M

Income Statement

Follow revenue through to earnings.

Revenue

$874.84M

FY 2025 · Annual

+94.1% YoY

Operating Income

$340.99M

FY 2025 · Annual

Net Income

$263.86M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue157.17M270.83M331.41M450.71M874.84M
Cost of Revenue7.26M6.59M4.66M12.49M19.08M
Gross Profit149.91M264.23M326.75M438.23M855.76M
Gross Margin95.4%97.6%98.6%97.2%97.8%
Research & Development208.81M253.3M216.57M174.64M166.13M
Selling, General & Admin118.82M159.37M213.89M266.13M348.65M
Operating Expenses327.63M412.67M430.46M440.77M514.77M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
EBITDA(121.74M)(143.85M)(116.34M)12.81M347.65M
EBITDA Margin-77.5%-53.1%-35.1%2.8%39.7%
Operating Income(177.72M)(148.44M)(103.71M)(2.54M)340.99M
Operating Margin-113.1%-54.8%-31.3%-0.6%39.0%
Interest Income62K5.13M15.78M14.75M10.67M
Interest Expense59.29M99.09M108.24M98.52M78.87M
Other Income / Expenses(4.09M)(95.95M)(122.52M)(84.41M)(73.6M)
Income Before Tax(181.81M)(244.38M)(226.23M)(86.95M)267.39M
Pre-Tax Margin-115.7%-90.2%-68.3%-19.3%30.6%
Income Tax Expense2.25M2.73M310K1.93M3.53M
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (Basic)(1.03)(1.33)(1.18)(0.43)1.26
EPS (Diluted)(1.03)(1.33)(1.18)(0.43)1.21
Weighted Avg Shares179.12M185.91M192.2M206.7M209.89M
Weighted Avg Shares (Diluted)179.12M185.91M192.2M206.7M218.58M

BCRX Earnings Waterfall · TTM

NASDAQ:BCRX · Revenue to Net Income

Key Ratios

EPS$-1.50
Gross Margin-13.8%
Net Margin-89.2%
P/E Ratio10.0
P/S Ratio10.1

Analysis

$940.6M of revenue converted into -$384.7M of net income for the selected period. Gross margin is -13.8% and net margin is -89.2%, showing how much revenue survives after costs and taxes. EPS is $-1.50, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026

How much revenue does BCRX generate?

BioCryst Pharmaceuticals, Inc. (BCRX) reported $874.84M of revenue in fiscal 2025.

Is BCRX profitable?

BioCryst Pharmaceuticals, Inc. (BCRX) reported $263.86M of net income, with a net margin of 30.2%.